Market Newsdesk

AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, today announced it has entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease.

“I am pleased with our success to date in being an effective collaborator with Evonik, a company with a long, successful and reliable track record of supporting pharmaceutical supply chains,” said Remi Barbier, President and CEO of Cassava Sciences.

“We are delighted to be collaborating with Cassava and contributing to fight Alzheimer’s together. We are committed to supporting Cassava in their goals to maintain the quality of life for millions of patients around the world and to further advance potential treatment options,” says Dr Thomas Riermeier, head of Evonik’s Health Care business line. Evonik is one of the world’s largest contract development and manufacturing organizations (CDMO) for active pharmaceutical ingredients and advanced intermediates.

About Evonik

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Cassava Sciences, Inc.

Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. For more information, please visit: https://www.CassavaSciences.com.

For More Information Contact:

Eric Schoen, Chief Financial Officer
[email protected]
(512) 501-2450 

Lakeland, FLA., March 09, 2021 (GLOBE NEWSWIRE) — Qgiv, a leading provider of nonprofit fundraising technology, was presented with a Silver Stevie® Award in the Customer Service Department of the Year category in the 15th annual Stevie Awards for Sales & Customer Service. The Stevie Awards for Sales & Customer Service are the world’s top honors for customer service, contact center, business development, and sales professionals.

Qgiv’s Customer Experience (CX) team meets and exceeds the expectations of their nonprofit clients through proactive outreach, free and unlimited support and training, and a deep-rooted passion for client success that’s evident in every interaction. The team’s efforts are reflected in a customer satisfaction score that has not dipped below 98% in the last five years.

“Having the opportunity to learn and grow with our clients over the years has been incredibly rewarding. The growth of our team from day one has consistently been focused on our clients’ experience and success, implementing programs and tools that better serve them,” said Jennifer Mansfield, vice president of customer experience at Qgiv. “Our passion for the success of the nonprofits we work with is fueled by the passion they show us every single day. They’re making an indelible mark for the better on the world, and we are fortunate to be a part of their journey.” 

When Qgiv was founded in 2007, customer support was first handled by a small group of founding members, included the company’s CEO, Todd Baylis. On top of managing the fledgling company’s operations, they took turns responding to client questions via email and phone.

Today, Qgiv provides user-friendly fundraising software to more than 5,000 nonprofit organizations across North America. The rapid growth Qgiv has experienced over the last 13 years has been accompanied by a rapidly growing support team and strategy.

Qgiv’s CX department now has a dedicated team that uses chat, NPS score tracking, support tickets, live workshops, and more to meet and exceed client expectations. Over the years, the Qgiv CX team has evolved to include onboarding, training, and customer success strategies to proactively help nonprofits exceed their goals. 

To address the challenges faced by nonprofit clients in 2020, Qgiv’s CX department shifted their in-person client events, called Fundraising Labs, to a virtual format. Each event served to educate clients on Qgiv’s functionality and arm nonprofits with the tools necessary to successfully fundraise in our new socially-distant reality. 

“In the toughest working environment in memory for most organizations, 2021 Stevie Award winners still found ways to innovate, grow sales, please their customers, and secure new business,” said Stevie Awards president Maggie Gallagher.  “The judges have recognized and rewarded this, and we join them in applauding this year’s winners for their continued success.  We look forward to recognizing them on April 14.” 

More than 2,300 nominations from organizations of all sizes and in virtually every industry, in 51 nations, were considered in this year’s competition. Winners were determined by the average scores of more than 160 professionals worldwide on nine specialized judging committees. Entries were considered in more than 90 categories for customer service and contact center achievements, including Contact Center of the Year, Award for Innovation in Customer Service, and Customer Service Department of the Year.

Details about the Stevie Awards for Sales & Customer Service and the list of Stevie winners in all categories are available at www.StevieAwards.com/Sales. 

About The Stevie Awards: Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Great Employers, the Stevie Awards for Women in Business, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

About Qgiv: Qgiv, Inc. is a leading digital fundraising platform founded in 2007. From their headquarters in Lakeland, FL, they currently serve more than 5,000 nonprofit organizations in the United States and Canada. Their no-contract pricing, unlimited access to tools and support, and integrations with leading CRM and email tools make it easy for nonprofits to experiment with new technology and grow their digital fundraising programs. Qgiv is committed to helping nonprofits raise more by anticipating and addressing their needs and challenges through customer-led development and close attention to industry best practices. To learn more about the Qgiv platform visit www.qgiv.com.

###

 

Attachments

• steviesannouncement_3_1200x630
• Stevies21_Silver_Winner

Melaina Chromy
Qgiv
[email protected]

Responding to the demands of remote work, Corel’s professional graphics suite enables designers to deliver flawless results faster and remain connected, even as teams work apart.

New versions of CorelDRAW Essentials & CorelDRAW Standard round out the 2021 lineup with apps for a full range of graphics users, including consumers, small businesses and graphics pros.

OTTAWA, March 09, 2021 (GLOBE NEWSWIRE) — Introducing the new CorelDRAW 2021 product lineup featuring professional graphic design software, CorelDRAW® Graphics Suite 2021. Available for Windows and Mac, the new suite doubles down on collaboration with access to next-generation tools that streamline the design and review process. Boost productivity with a flexible design space that empowers users to take control of projects and assets. Advanced illustration and photo editing capabilities make it faster than ever for designers to achieve their unique creative vision. And as our definition of workplaces is continuously redefined, CorelDRAW.app™ is now touch-optimized and available as an all-new iPad app, giving graphics pros new options to be creative anywhere, from virtually any device.

“The way we work has changed faster than anyone could imagine, and CorelDRAW Graphics Suite 2021 is meeting this need head on. At a time when it’s never been more challenging and important to stay connected, our collaboration tools enable teams to share inspiration and feedback in real time, whether they’re across town or across the globe,” said John Falsetto, Senior Director of Products, Graphics and Productivity. “By re-examining users’ workflows and making extensive enhancements across the suite, we’re helping designers take their projects from ideation to final output, faster.”

Offering vector illustration, layout and typography, photo editing and more, CorelDRAW Graphics Suite 2021 simplifies complex workflows and gives designers total control over how they create their best work – on Windows, Mac, web and mobile. Focusing on collaboration, productivity, and flawless results, new highlights include:

Time saving, next-generation collaboration makes it possible to connect, keep projects on track, and work together from anywhere – in real time.

• NEW! Dashboard: The dashboard in both CorelDRAW® 2021 and CorelDRAW.app acts as a collaboration hub containing all design files in the cloud, and in a click, displays a preview, the number of comments and team members, and project status. Share designs directly from CorelDRAW 2021 without having to open each file.
• NEW! Live Comments: Reviewers and approvers can now comment on and annotate a document in CorelDRAW.app, with instant feedback appearing in the designer’s working file in the CorelDRAW 2021 application on their Windows or Mac system. Sharing notes and comments in real time eliminates slowdowns and accelerates approvals.
• NEW! Microsoft Teams Integration: Enterprise customers can view and edit design files using CorelDRAW.app for Teams. Sign in with a Microsoft 365 corporate user account to create new designs, and collaboratively review designs with team members right inside Teams channels.

All-new, flexible design space allows users to work more efficiently and with greater control over their projects and assets.

• NEW! Multipage View: View, manage, and edit all of your project’s digital assets in one view. Move and copy objects across pages, compare designs side-by-side, and freely move pages around to arrange them as you wish.
• NEW! Pages docker/inspector: The Pages docker/inspector lists all pages in a design with a new thumbnail grid view, making it easier to manage and sort your pages. Navigate your projects, add, delete, and rename pages, and with a click, switch display modes to either focus on a single page or use the new Multipage View.
• NEW! Multi-asset Export: Save time with a flexible range of options for outputting pages and objects, plus create a customized list of assets to export with one click. Simultaneously export the same design element at different sizes, resolutions, and file formats – ideal for web and mobile app design tasks – or easily export several items using identical settings. Send pages or objects to multiple industry-standard formats, including PDF.

Advanced illustration features deliver stunning results in record time with precise layout capabilities and innovative tools that simplify complicated workflows.

• NEW! Perspective Drawing: Draw objects or illustrated scenes in perspective, faster and easier than ever. Choose from 1, 2, or 3- point perspective, draw or add an existing group of objects on a shared perspective plane, and move and edit objects freely without losing perspective.
• ENHANCED! Guidelines & NEW Snap to Self: Manage custom guidelines and switch views from world scale to page dimensions with one click. Plus, with Snap to Self, quickly and precisely move and transform design elements with the new ability to turn snapping behaviors on and off.

With progressive photo editing, C
orel PHOTO-PAINT™ 2021
delivers a faster, easier route to flawless images that exceed client expectations.

• NEW! Adjustments docker/inspector: Get instant access to the most critical and frequently used filters to work non-destructively, in real time, and in context. Quickly isolate objects and areas within your images using the new Local Adjustments Mode. Plus, save settings for reuse and customize favorite filters to get started right away.
• NEW! Replace Colors: Available in the new Adjustments docker/inspector, Replace Colors allows you to make targeted and polished edits to an image’s hue, saturation, and lightness. With this improved color workflow, designers can achieve more natural photo editing results, dramatically faster than before.
• NEW! HEIF support: Take advantage of photos captured on iPhones with High Efficiency Image File Format (HEIF) support, now in both Corel PHOTO-PAINT and CorelDRAW 2021.

CorelDRAW is everywhere! Say hello to a true cross-platform experience on Windows, Mac, web, iPad, and other mobile devices.

• NEW! Native support for Apple silicon: CorelDRAW Graphics Suite 2021 for Mac is built to take advantage of the exceptional power and performance of the Apple M1 chip. Plus, enjoy menus, windows and views, fields and labels, buttons, and other UI elements that reflect the latest in macOS Big Sur.

• ENHANCED! Touch-optimized CorelDRAW.app: With a new touch-optimized user experience, the CorelDRAW.app web application expands what’s possible on mobile and tablets.

• NEW! CorelDRAW.app for iPad: A new iPad app makes it even easier to design on the go while also letting you review and annotate shared design files from anywhere.

• ENHANCED! Display performance on Windows 10: CorelDRAW Graphics Suite 2021 is optimized to fully leverage your Windows system’s GPU to deliver up to 14.6 times smoother panning and 4.4 times smoother zooming.

The CorelDRAW 2021 product lineup offers graphics solutions to meet a full range of creative needs.

Corel also introduces the new CorelDRAW Essentials 2021 and CorelDRAW Standard 2021, offering creative consumers and home businesses powerful, cost-effective solutions tailored specifically to their needs. For more information, pricing and comparison information, please visit: www.coreldraw.com/family.

CorelDRAW Graphics Suite 2021 Availability and Pricing

Available for Windows and Mac, CorelDRAW Graphics Suite 2021 extends its language support with a new Swedish version, in addition to suites available in English, German, Italian, French, Spanish, Brazilian Portuguese, Dutch, Polish, Czech, Russian, Simplified Chinese, Traditional Chinese, Turkish, and Japanese. Subscription is $249 USD / €349 / £299 per year. Perpetual licenses are available at the suggested retail price of $499 USD / €719 / £599. EUR and GBP prices include VAT.

CorelDRAW.app collaboration features are available exclusively with a CorelDRAW Graphics Suite subscription, licensing with maintenance, or an additional CorelDRAW.app Pro subscription for perpetual license customers.

CorelDRAW.app for Microsoft Teams is available exclusively with CorelDRAW.app Enterprise, part of the CorelDRAW Business & Enterprise offering and requires a Microsoft 365 account. To learn more about enterprise licensing options, including volume licensing, maintenance, software deployment, and virtualization, please visit: www.coreldraw.com/business.

For more information and to download the free trial, visit www.coreldraw.com.

About Corel

Corel products enable millions of connected knowledge workers around the world to do great work faster. Offering some of the industry’s best-known software brands, we give individuals and teams the power to create, collaborate, and deliver impressive results. Our success is driven by an unwavering commitment to deliver a broad portfolio of innovative applications – including CorelDRAW®, MindManager®, Parallels®, and WinZip® – to inspire users and help them achieve their goals. To learn more about Corel, please visit www.corel.com.

©2021 Corel Corporation. All rights reserved. Corel, the Corel logo, the Corel Balloon logo, CorelDRAW, CorelDRAW.app, Corel PHOTO-PAINT, MindManager, and WinZip are trademarks or registered trademarks of Corel Corporation in Canada, the U.S., and/or elsewhere. Parallels is a trademark or registered trademark of Parallels International GmbH in Canada, the U.S. and elsewhere. Apple, iPad, iPhone, Mac and macOS are trademarks of Apple Inc. All other company, product and service names, logos, brands and any registered or unregistered trademarks mentioned are used for identification purposes only and remain the exclusive property of their respective owners. Use of any brands, names, logos or any other information, imagery or materials pertaining to a third party does not imply endorsement. We disclaim any proprietary interest in such third-party information, imagery, materials, marks and names of others. For all notices and information about patents, please visit www.corel.com/patent.

Media Contact

Ashley Ruess
PR Manager
[email protected]
www.coreldraw.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/d9df982b-9941-4d55-a9ed-2cf6e532acea

https://www.globenewswire.com/NewsRoom/AttachmentNg/d044981a-e983-49c2-86fe-256df4571e51

https://www.globenewswire.com/NewsRoom/AttachmentNg/e03dc1cb-344e-40b8-949e-d10d6dd537df

https://www.globenewswire.com/NewsRoom/AttachmentNg/59120a1b-e625-4233-92f0-bd098381a04c

https://www.globenewswire.com/NewsRoom/AttachmentNg/b92499dc-607f-4713-9ae3-e9222a8ccbce

https://www.globenewswire.com/NewsRoom/AttachmentNg/185026fa-4098-495d-9b61-9a22fbf42788

A video accompanying this announcement is available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/9c7b39ba-5293-4318-9816-c17c12e85a6b

VANCOUVER, British Columbia, March 09, 2021 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce a service agreement with the IMPACT Clinical Trial Accelerator Program housed within Alberta’s Life Sciences Innovation Hub at the University of Calgary.

Optimi instituted a program in 2020 to identify and engage with a suitable partner in its quest to become one of the first companies to utilize natural psilocybin mushrooms as a primary component for product formulization and requisite clinical trial efforts. Optimi’s overarching philosophy and commitment to the use of all-natural ingredients in its products is a key differentiator to those industry competitors who have committed to the production of laboratory produced synthetic psilocybin compounds.

Optimi’s JJ Wilson, (Board Chair), notes, “In order to use naturally harvested psilocybin mushrooms for a clinical trial, the psilocybin must first be grown in a GMP grade facility. For this reason, we are extremely excited regarding the long-term potential of our 20,000 sq. ft. purpose-built facilities in Princeton, BC. There is extensive historical information on naturally derived psilocybin formulas and its uses for a variety of healing purposes, yet right now there is a shortage of regulated GMP supply for natural psychedelic mushrooms. We hope to change this soon.”

The IMPACT program provides Optimi expert clinical support towards commercializing proposed psilocybin-based formulations through the conduct of clinical trials and expert assistance towards securing regulatory approval. The program works to design, support, execute, and report on the clinical trial process in conjunction with a Principal Investigator. IMPACT offers unparalleled access to research space (offices, wet and dry labs, prototype spaces), entrepreneurial and business development programming, mentorship, and connection to additional experts, facilities, and resources.

The Optimi team believes that the way forward for the treatment of various disorders such as anxiety, depression, PTSD, and even alcoholism appears promising for the use of proprietary novel formulations derived from natural psychedelic mushrooms. Optimi will provide pharmaceutical grade mushrooms cultivated and processed under controlled conditions to maintain consistent grade and potency. The Company is focused on becoming the natural alternative to synthetic alternatives and is positioning itself to become the premier cultivator of pharmaceutical-grade psilocybin mushrooms for clinical use.

Company CEO, Mike Stier adds, “Today’s announcement is indicative of how we plan to proceed. It builds on our recent news (March 2nd) regarding our R&D agreement with Numinus Wellness as part of an integrated plan to accelerate our value proposition. We aim to develop primarily natural formulations and superior processes with intrinsic value as intellectual property (IP), and we intend to achieve this by expanding our relationships with academic and industry participants including dedicated researchers, doctors, and business leaders across the nation and beyond. We are equally focused on ensuring we operate with good governance and top-level guidance within a solid leadership framework committed to generating value for our stakeholders and shareholders alike.”

On Behalf of the Board of Directors, Optimi Health Corp.
Mike Stier
President, Chief Executive Officer and Director

ABOUT OPTIMI (CSE: OPTI)

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.
Find out more at: https://optimihealth.ca/.

FOR FURTHER INFORMATION CONTACT:

Investor Relations
Email: [email protected]
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

• Sorrento is moving forward with the research and development of COVISHIELD antibody combinations with potentially potent neutralizing activities against early COVID-19 pandemic virus isolates as well as current variants of concern.
• Pre-clinical development of an antibody combination therapeutic including Sorrento and Mount Sinai antibodies for intravenous (IV) and intranasal administration is underway.
• This step in the fight against COVID-19 follows the progress made with Sorrento’s intravenous STI-2020 (COVI-AMG™) that completed Phase 1 safety studies in healthy volunteers and is now in Phase 2 studies for mild to moderate COVID-19 patients in outpatient and inpatient settings; and Sorrento’s intranasal STI-2099 (COVIDROPS™) that is being tested in Phase 1 studies in healthy volunteers and mild to moderate COVID-19 patients.

SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced major progress in the development of COVISHIELD through the license of intellectual property developed by the scientific team at the Icahn School of Medicine at Mount Sinai (“Mount Sinai”). Sorrento and Mount Sinai have entered into an Exclusive License Agreement for a collection of antibodies having SARS-CoV-2 neutralizing properties that were developed by Mount Sinai.

The license also contemplates Sorrento and Mount Sinai pursuing future collaborations in developing humanized monoclonal antibodies for therapeutic applications.

COVISHIELD, which is under development, will be a combination of two monoclonal antibodies designed to protect against disease caused by existing and emerging variants of SARS-CoV-2. Using the early pandemic variants as well as the emerging variants of concern (“VOCs”) that have increased in prevalence globally through the course of the pandemic, Sorrento identified candidate monoclonal antibody combinations, or “cocktails”, with potent activity against the breadth of these VOCs, including the United Kingdom (B.1.1.7), South Africa (B.1.351), and Japan/Brazil (B.1.128) variants. Positive results from these laboratory studies are expected to support the future research path and FDA evaluation of COVISHIELD.

COVISHIELD represents a coordination of the discovery and development resources of Sorrento, incorporating intellectual property developed by Mount Sinai, in order to provide a rapid and dynamic means of responding to changes in the public health burden posed by coronaviruses and similar pandemic threat pathogens. Sorrento is developing capabilities and solutions with a goal of contributing to pandemic readiness.

Sorrento Chairman and CEO, Dr. Henry Ji, commented, “We are pleased with the excellent COVISHIELD antibody candidates identified thus far, and we at Sorrento are committed to rapidly developing the COVISHIELD cocktail against known and emerging COVID-19 variants of concern. Sorrento looks forward to future collaborations with the respected research capabilities of Mount Sinai centered on the development of innovative anti-viral and anti-cancer therapeutic candidates.”

About Sorrento Therapeutics, Inc.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.

Sorrento’s commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido^® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido^® was approved by the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the neutralizing capabilities of COVISHIELD antibody combinations and potential effectiveness against COVID-19 and any variants of the disease; the therapeutic potential of COVISHIELD for SARS-CoV-2 and COVID-19 disease; the potential clinical relevance and/or significance of clinical studies of STI-2020 and STI-2099; any future agreements or collaborations that may be entered into or occur, respectively, between Sorrento and Mount Sinai; the efficacy of candidate monoclonal antibody combinations against Sars-CoV-2 and any emerging variants of concern; expectations regarding results of laboratory studies of COVISHIELD, and the potential for any results to support the future research path and FDA evaluation of COVISHIELD; Sorrento’s and Mount Sinai’s ability to provide a rapid and dynamic means of responding to changes in public health burden posed by coronaviruses and similar pandemic threat pathogens; expectations regarding Sorrento’s development of capabilities and solutions to contribute to pandemic readiness; Sorrento’s commitment to rapidly developing and commercializing COVISHIELD against known and emerging COVID-19 variants of concern; and Sorrento’s potential position in the diagnostics testing and therapeutics industries. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento’s and its subsidiaries’, affiliates’ and partners’ technologies and prospects and collaborations with partners, including, but not limited to risks related to conducting pre-clinical and clinical studies and seeking regulatory approval for COVISHIELD, including the timing for receipt of any such approval; conducting and receiving results of clinical trials; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its COVID-19 therapeutic product candidates strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento’ most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Contact


Alexis Nahama, DVM (SVP Corporate Development)
Email: [email protected]

Sorrento^® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB™, DAR-T™, SOFUSA™, COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and COVISTIX™ are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA™ is a trademark of Semnur Pharmaceuticals, Inc.

ZTlido^® is a registered trademark owned by Scilex Pharmaceuticals Inc.

All other trademarks are the property of their respective owners.

©2021 Sorrento Therapeutics, Inc. All Rights Reserved.

Sullivan to focus on equipping banks and credit unions in the West with solutions for improving the customer experience (CX), fighting financial fraud, and increasing operational efficiency

TULSA, OK, March 09, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — FinTech enablement company ENACOMM is continuing to invest in industry talent with its new hire of John Sullivan as Regional Vice President of Financial Services. Based in Southern California, Sullivan will be charged with bringing the ENACOMM Financial Suite (EFS) to financial institutions in the western United States, the company today announced.

The ENACOMM Financial Suite provides a range of software tools, from powerful voice biometrics to customer relationship management (CRM), as well as added levels of security. Unlike systems with limited verbiage or number-specific options in a standard menu, ENACOMM’s data-powered interactive voice response (IVR) solution responds to verbal customer requests with human-like understanding. The technology uses customer intelligence to efficiently direct calls, personalization to help retain bank customers and credit union members, and context preservation to offer fast, seamless self-service.

Sullivan brings more than two decades of experience with helping customers minimize cost and maximize productivity through the strategic implementation of technology solutions. Most recently, he served as Channel Director of the Western United States for Unify Software and Solutions—a member of the Atos family—where he successfully drove significant revenue growth and received global recognition for Alliance Partner success. Prior to his five years at Unify, Sullivan stacked achievements in business development, sales and IT consulting while working for Technology Integration Group, VOX Network Solutions and Integrated Technology.

“ENACOMM is committed to building our team with top industry experts who can expertly problem-solve through the application of technology, while playing instrumental roles supporting ENACOMM’s next phase of growth,” said Michael Boukadakis, ENACOMM Chairman & CEO. “John Sullivan is a tech sector superstar who has extensive knowledge and experience in forging industry partnerships and rapidly generating revenue growth, with a consultative approach that delivers exceptional value to customers.”

At ENACOMM, Sullivan will parlay his expertise into meeting financial institutions’ technology needs through ENACOMM’s affordable, data-driven solutions for improving the customer experience (CX), fighting financial fraud, and increasing operational efficiency. The company has been empowering banks, credit unions, and credit card and payment companies with transformational technologies for 35 years.

“ENACOMM set itself apart with affordable, modern technology that enables community financial institutions to achieve competitive parity, despite lacking big banks’ IT staff or budget for R&D,” shared Sullivan. “I couldn’t be more excited to join the ENACOMM team and connect banks and credit unions on the left side of the map with solutions that will dramatically upgrade their digital capabilities and strengthen their market position.”

To learn more about ENACOMM’s FinTech solutions, go to www.enacomm.net.

About ENACOMM

ENACOMM is a FinTech provider of intelligent interactions and customer authentication technologies for banks, credit unions, credit card and payments companies, as well as a digital gateway that enables financial services companies to innovate by overcoming the complexities of integrating to core, payments, and other digital platforms. ENACOMM was named a “Top 10 Retail Banking Solution Provider” by Banking CIO Outlook magazine. The company empowers financial institutions with affordable solutions for improving the customer experience (CX), fighting financial fraud, and increasing operational efficiency. A frontrunner in self-service technologies including interactive voice response (IVR) for over three decades, ENACOMM solutions are delivered as hosted services or on-demand through the “cloud.” The company’s customer base ranges from community credit unions and community banks to the largest financial institutions in the United States. Utilizing web, mobile, SMS texts, email, voice, chatbots and other communication technology channels including digital voice assistants, ENACOMM harnesses artificial intelligence, big data, voice biometrics and more to help organizations provide customers with a superior, omnichannel self-service experience that includes Conversational Voice Banking. ENACOMM processes more than 1,000,000 customer interactions and automated data transactions every day. For more information, go to www.enacomm.net.

For more information, contact:

Lauren DuBois

(917) 573-2485

[email protected]